Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

K U Laval

Showing results (1-10 of 12) with videos related to

Pageof 2
Sort By:
European Urology|January 1, 1979
Paranephric abscess: a changing conceptK U Laval, W Lutzeyer
Die Medizinische Welt|March 23, 1973
[Acute pyelonephritis]K U Laval, R Rohrbach
Urologia Internationalis|January 1, 1980
Spontaneous phasic activity of the detrusor: a cause of uninhibited contractions in unstable bladders?K U Laval, W Lutzeyer
Der Urologe. Ausg. A|September 1, 1976
[Vesicoureterorenal reflux: an inherited disease? (author's transl)]K U Laval, P Rathert
Der Urologe. Ausg. A|January 1, 1978
[Pseudotumor of the renal pelvis during nonspecific inflammatory granuloma (author's transl)]K U Laval, K H Bigalke
Urologia Internationalis|January 1, 1978
Effects of beta-adrenergic stimulating and blocking agents on the dynamics of the human bladder outletK U Laval, J Hannappel, W Lutzeyer
Journal D'Urologie Et De Nephrologie|January 1, 1976
[Septic kidney (acute clinical aspect)]G Durben, K U Laval, P Rathert, et al.
Der Urologe. Ausg. A|May 1, 1980
[The septic kidney: primary nephrectomy or conservative surgery? A clinical study of 110 cases (author's transl)]K U Laval, G Durben, P Rathert, et al.
European Urology|May 10, 2002
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension studyP van Kerrebroec, A Jardin, P van Cangh, et al.
European Urology|March 18, 2000
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study GroupP van Kerrebroeck, A Jardin, K U Laval, et al.
Pageof 2

Showing results (1-10 of 12) with videos related to

Sort By:
Pageof 2
European Urology|January 1, 1979
Paranephric abscess: a changing conceptK U Laval, W Lutzeyer
Die Medizinische Welt|March 23, 1973
[Acute pyelonephritis]K U Laval, R Rohrbach
Urologia Internationalis|January 1, 1980
Spontaneous phasic activity of the detrusor: a cause of uninhibited contractions in unstable bladders?K U Laval, W Lutzeyer
Der Urologe. Ausg. A|September 1, 1976
[Vesicoureterorenal reflux: an inherited disease? (author's transl)]K U Laval, P Rathert
Der Urologe. Ausg. A|January 1, 1978
[Pseudotumor of the renal pelvis during nonspecific inflammatory granuloma (author's transl)]K U Laval, K H Bigalke
Urologia Internationalis|January 1, 1978
Effects of beta-adrenergic stimulating and blocking agents on the dynamics of the human bladder outletK U Laval, J Hannappel, W Lutzeyer
Journal D'Urologie Et De Nephrologie|January 1, 1976
[Septic kidney (acute clinical aspect)]G Durben, K U Laval, P Rathert, et al.
Der Urologe. Ausg. A|May 1, 1980
[The septic kidney: primary nephrectomy or conservative surgery? A clinical study of 110 cases (author's transl)]K U Laval, G Durben, P Rathert, et al.
European Urology|May 10, 2002
Long-term safety and efficacy of a once-daily formulation of alfuzosin 10 mg in patients with symptomatic benign prostatic hyperplasia: open-label extension studyP van Kerrebroec, A Jardin, P van Cangh, et al.
European Urology|March 18, 2000
Efficacy and safety of a new prolonged release formulation of alfuzosin 10 mg once daily versus alfuzosin 2.5 mg thrice daily and placebo in patients with symptomatic benign prostatic hyperplasia. ALFORTI Study GroupP van Kerrebroeck, A Jardin, K U Laval, et al.
Pageof 2